Navigation Links
UT-Battelle licenses tissue regeneration technologies to NellOne Therapeutics, Inc.
Date:1/28/2010

OAK RIDGE, Tenn., Jan. 28, 2010 -- In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of the Department of Energy laboratory.

The protein therapy treatment under development takes advantage of the Nell-1 gene's cell-signaling pathway that controls tissue growth and maturation in mammalian organs.

The foundation for this therapy is research performed by Cymbeline Culiat, who as an ORNL systems genetics researcher identified the role that the Nell-1 pathway plays in tissue growth and maturation.

Today, Culiat is leading the NellOne research effort to translate the Nell-1 pathway discoveries into a therapy that restores both mass and function to damaged human tissues, such as heart and skeletal muscle.

If successful, the protein therapy could improve the lives of victims of heart attacks and severe muscle wounds. Other therapies, such as stem-cell treatments, have succeeded in triggering tissue formation but fall short in restoring the actual function of the tissue.

Battelle Ventures, with its Knoxville-based affiliate fund, Innovation Valley Partners (IVP), created NellOne with a $1.5-million seed investment in 2008.

"Our executing this license is confirmation from NellOne that sufficient proof-of-principle experiments have been completed and that the company is progressing toward the commercialization of an extremely promising technology that could one day vastly improve the lives of countless heart patients," said Tracy Warren, NellOne chief executive officer and Battelle Ventures general partner.

"NellOne is currently dedicated to the development of intellectual property and moving into a clinical setting," Warren continued, noting that it operates out of the IVP office in Knoxville. "A medical treatment based on the patented technologies is years away, making Battelle Ventures' support even more critical."

"This licensing agreement is a statement not only of NellOne's promise, but also of how vital the support of venture capital investment is during these crucial early years of technology development and nurturing," said ORNL Partnerships Director Tom Ballard. "This announcement is an important step along the way to the marketplace past the initial proof-of-concept stage."


'/>"/>

Contact: Bill Cabage
cabagewh@ornl.gov
865-574-4399
DOE/Oak Ridge National Laboratory
Source:Eurekalert

Related biology news :

1. Virginia Tech licenses GenoCAD source code to ISCB
2. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
3. MSU licenses plant oil enhancement technology to BASF Plant Science
4. UGA licenses technology to make fuel from dead forests and agricultural waste
5. UGA licenses new Bermuda grass that thrives in sun and shade
6. UGA licenses invention that kills food-borne pathogens in minutes
7. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
8. Syntermed licenses Emory ERTb software for enhanced cardiac imaging
9. $3.75 million grant advances tissue engineering partnership
10. New pathway discovered that may prevent tissue damage resulting from inflammation
11. Supportive materials will help regenerate heart tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
Breaking Biology News(10 mins):
(Date:4/20/2017)...  Eli Lilly and Company (NYSE: LLY ... the prevention of migraine at the American Academy of ... 22-28, 2017, in Boston . ... including safety and patient outcomes data for galcanezumab in ... in monthly migraine headache days among patients with episodic ...
(Date:4/20/2017)... Kong (PRWEB) , ... April 20, 2017 , ... NetDimensions ... Global Sales. , With over 20 years of experience in the learning technologies industry, ... a sister company within Learning Technologies Group plc (LTG). At LEO, Mastin served as ...
(Date:4/20/2017)... ... 20, 2017 , ... Parallel6™ , the leader in mClinical™ technologies for ... were named one of the 2017 Top 10 eClinical Trial Management Solution Providers ... industry. , “We take pride in honoring Parallel6 as one of the top 10 ...
(Date:4/20/2017)... Israel , April 20, 2017  BrainStorm Cell ... cell technologies for neurodegenerative diseases, announced today that Chaim ... for Regenerative Medicine,s (ARM) 5 th Annual Cell & ... 09:40 EDT in Boston . ... Medical Officer & Chief Operating Officer, will participate in a ...
Breaking Biology Technology: